A Phase 1 interventional study of sitaxentan and tadalafil in Pulmonary Arterial Hypertension, sponsored by Pfizer. Terminated at 1 site in Singapore. Open to participants aged 21 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2012-02-22.
Sponsored by Pfizer · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Pulmonary Arterial Hypertension by Pfizer — none open to participants now, none under way, none of them phase 3. Pulmonary Arterial Hypertension · Pfizer.
Among the 11 studies in Pulmonary Arterial Hypertension by Pfizer, this one is one of 4 that started in 2010, is one of 3 in phase 1, and was the 6th registered.
700 studies on the registry are indexed under Pulmonary Arterial Hypertension; 141 are open to participants now.
Browse Pulmonary Arterial Hypertension studies →None of the 11 studies in Pulmonary Arterial Hypertension by Pfizer is open now. The open studies under Pulmonary Arterial Hypertension, anywhere →
Of the 90 Pulmonary Arterial Hypertension studies recruiting now, 51 (57%) set no upper age limit and 24 (27%) stop at 75 or younger; 18 take children under 18; 11 take healthy volunteers.
This study: 21 Years to 55 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 1 · Phase 3 4
First in 2003; this study’s year is marked. 4 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 16 is below the median of 40 across 478 interventional studies indexed under Pulmonary Arterial Hypertension.
Median enrollment 57 across the 8 interventional studies, 54 across the 3 observational. Of the 9 that completed or were terminated, 7 (78%) have results posted.
This tab as a report to print or save as PDF → With an account.
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 11 studies in Pulmonary Arterial Hypertension by Pfizer, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Sitaxsentan has a low drug-drug interaction potential and it did not have a clinically relevant effect on pharmacokinetics of sildenafil (a CYP3A sensitive substrate and PDE5 inhibitor).
Tadalafil did not have clinically relevant effect on pharmacokinetics of bosentan and ambrisentan. Based on overall clinical drug-drug interaction profiles, and in vitro CYP enzymes and transporter data, a clinically relevant drug-drug interaction between sitaxsentan and tadalafil is not expected. Sildenafil is not expected to affect sitaxsentan pharmacokinetics (PK), as sitaxsentan is a substrate of CYP3A4 and CYP2C9, where sildenafil did not show clinically relevant effect on PK of substrates of CYP3A4 and CYP2C9.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
sitaxsentan 100 mg QD for 6 days (Treatment A)
Drug: sitaxentan
tadalafil 40 mg QD for 6 days
Drug: tadalafil
sitaxsentan 100 mg QD co-administered with tadalafil 40 mg QD for 6 days
Drug: sitaxsentan · Drug: tadalafil
sitaxsentan 100 mg QD co-administered with sildenafil 20 mg TID for 6 days
Drug: sitaxsentan · Drug: sildenafil
sitaxsentan 100 mg QD for 6 days
Also known as: Thelin
tadalafil 40 mg QD for 6 days
sitaxsentan 100 mg QD for 6 days
tadalafil 40 mg QD for 6 days
sitaxentan 100 mg QD for 6 days
sildenafil 20 mg TID for 6 days
Time to Reach Maximum Observed Plasma Concentration (Tmax)
Time frame: Day 6 (predose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, and 24 hours post dose)
Trough Plasma Concentrations (Ctrough)
Minimum or "trough"concentrations
Time frame: Day 6 (predose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, and 24 hours post dose)
Maximum Observed Plasma Concentration (Cmax)
Time frame: Day 6 (predose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, and 24 hours post dose)
Area Under the Curve of the 24 Hour Dosing Interval (AUC24)
Time frame: Day 6 (predose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, and 24 hours post dose)
Apparent Oral Clearance (CL/F)
Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Clearance was estimated from population pharmacokinetic (PK) modeling. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.
Time frame: Day 6 (predose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, and 24 hours post dose)
Volume of Distribution at Steady State (Vss)
Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug. Steady state volume of distribution (Vss) is the apparent volume of distribution at steady-state.
Time frame: Day 6 (predose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, and 24 hours post dose)
Plasma Decay Half-Life (t1/2)
Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.
Time frame: Day 6 (predose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, and 24 hours post dose)
The study was terminated for safety reasons (hepatoxicity) after dosing was completed for the first intervention.
| Milestone | Sitax, Then Tad, Then Sitax and Tad, Then Sitax and Sild | Tad, Then Sitax and Sild, Then Sitax, Then Sitax and Tad | Sitax and Tad, Then Sitax, Then Sitax and Sild, Then Tad | Sitax and Sild, Then Sitax and Tad, Then Tad, Then Sitax |
|---|---|---|---|---|
| Started | 4 | 4 | 4 | 4 |
| Completed | 0 | 0 | 0 | 0 |
| Not completed | 4 | 4 | 4 | 4 |
| Withdrew: Study terminated | 4 | 4 | 4 | 4 |
No measurements were reported for this outcome.
Minimum or "trough"concentrations
No measurements were reported for this outcome.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Clearance was estimated from population pharmacokinetic (PK) modeling. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.
No measurements were reported for this outcome.
Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.
No measurements were reported for this outcome.
Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug. Steady state volume of distribution (Vss) is the apparent volume of distribution at steady-state.
No measurements were reported for this outcome.
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Sitaxsentan | — | 0/4 (0%) | 1/4 (25%) |
| Tadalafil | — | 0/4 (0%) | 4/4 (100%) |
| Sitaxsentan and Tadalafil | — | 0/4 (0%) | 4/4 (100%) |
| Sitaxsentan and Sildenafil | — | 0/4 (0%) | 2/4 (50%) |
| Event | Sitaxsentan | Tadalafil | Sitaxsentan and Tadalafil | Sitaxsentan and Sildenafil |
|---|---|---|---|---|
| HeadacheNervous system disorders | 1/4 | 3/4 | 3/4 | 0/4 |
| NauseaGastrointestinal disorders | 0/4 | 2/4 | 2/4 | 0/4 |
| PyrexiaGeneral disorders | 0/4 | 2/4 | 2/4 | 1/4 |
| Back painMusculoskeletal and connective tissue disorders | 0/4 | 2/4 | 0/4 | 0/4 |
| MyalgiaMusculoskeletal and connective tissue disorders | 1/4 | 2/4 | 2/4 | 0/4 |
| Head discomfortNervous system disorders | 0/4 | 2/4 | 0/4 | 0/4 |
| InsomniaPsychiatric disorders | 0/4 | 1/4 | 2/4 | 0/4 |
| Abdominal distensionGastrointestinal disorders | 1/4 | 0/4 | 0/4 | 0/4 |
| DiarrhoeaGastrointestinal disorders | 1/4 | 0/4 | 1/4 | 1/4 |
| DysphagiaGastrointestinal disorders | 0/4 | 1/4 | 1/4 | 1/4 |
| Age Continuous(years) | Entire Study Population |
|---|---|
| Mean | 31.9 ± 7.7 |
| Sex: Female, Male(Participants) | Entire Study Population |
|---|---|
| Female | 0 |
| Male | 16 |
The record gives a start of Nov 2010, a primary completion of Dec 2010 and a completion of Dec 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2012, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jan 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Sitaxsentan · Tadalafil · Sildenafil
Pulmonary Arterial Hypertension →